interleukin

(redirected from Interleukin-17)
Also found in: Dictionary, Thesaurus, Medical.
Related to Interleukin-17: IL-17F

interleukin

a substance extracted from white blood cells that stimulates their activity against infection and may be used to combat some forms of cancer

interleukin

[‚in·tər′lü·kən]
(immunology)
Any of a class of proteins that are secreted mostly by macrophages and T lymphocytes and induce growth and differentiation of lymphocytes and hematopoietic stem cells.
References in periodicals archive ?
Nobata et al., "Interleukin-17 levels in Helicobacter pylori-infected gastric mucosa and pathologic sequelae of colonization," World Journal of Gastroenterology, vol.
Cao, "Interleukin-17 and its expanding biological functions," Cellular & Molecular Immunology, vol.
Taanman-Kueter et al., "Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells," Immunity, vol.
The effects of vitamin D on allergen-induced expression of interleukin-13 and interleukin-17 in cord blood [CD4.sup.+] T cells.
The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models.
(Levels of interleukin-17 in patients with periodontal disease).
The signature cytokine, interleukin-17 (IL-17), combined with other proinflammatory cytokines (e.g., IL-6, TNF-[alpha], IL-1, and IL-8) induced by IL-17 contributes to the promotion of disruptive enzymes such as metalloproteinase-9 [40, 42, 43].
The granted claims cover the use of these cell populations to reduce levels of inflammatory cytokines TNF-alpha, interleukin-6, and interleukin-17, all established mediators of inflammatory arthritis in rheumatic diseases.
This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies- interleukin-17 (IL-17) inhibitors (Cosentyx, guselkumab and tildrakizumab), interleukin-23 (IL-23) inhibitors (ixekizumab and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla (apremilast).
Opportunistic infections in adult patients can also be a presentation of autoantibodies that inhibit cytokines including (but not only) anti interferon-gamma (anti IFN-?) self-antibodies in previously healthy adults presenting with severe Mycobacterial infections (4) or antibodies to interleukin-17 (IL-17) and IL-22 that are associated with chronic candidiasis (5) this group of autoantibodies are now recognized as phenocopies or acquire immune disorders resembling primary genetic immunodeficiency diseases (6).
Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis.